Arkolith/Insider Trading/TERN/Form 4

Gengos Andrew

Chief Financial OfficerTerns Pharmaceuticals, Inc. (TERN) · full profile →Form 4 · filed May 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 5, 2026Tender(U)41K$53.00$2.1M0
May 5, 2026Disposed to issuer(D)69K$53.00$3.6M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 5, 2026Disposed to issuer(D)750K——0
May 5, 2026Disposed to issuer(D)138K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001563623-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML